Printer Friendly

BRADLEY PHARMACEUTICALS REPORTS RESULTS

 BRADLEY PHARMACEUTICALS REPORTS RESULTS
 FAIRFIELD, N.J., March 11 /PRNewswire/ -- Bradley Pharmaceuticals,


Inc. (NASDAQ: BPRXA), reported today that sales for the fourth quarter ending December 1991 rose 76 percent to approximately $405,000 from the similar period in 1990. Sales for the 12 months rose 38 percent to approximately $1,130,000.
 The sales increase in the fourth quarter was substantially due to the recent acquisition of Duadacin, a cold capsule from Hoechst-Roussel Pharmaceuticals Inc., and a good flu/cold season.
 BRADLEY PHARMACEUTICALS, INC.
 Quarter to Dec. 31 1991 1990
 Revenue $ 404,998 $ 230,074
 Net loss $ (14,160) $ (78,585)
 Share loss $(.01) $(.04)
 Year to Dec. 31 1991 1990
 Revenue $1,130,570 $ 816,346
 Net loss $ (271,519) $ (622,404)
 Share loss $(.12) $(.29)
 Shares outstanding 2,175,000 2,175,000
 Bradley Pharmaceuticals, Inc., markets ethical prescription and non- prescription pharmaceuticals in five categories: hematinics, cough/cold, nutritionals, cardiovascular, and dermatology. It acquires non- strategic products from major pharmaceutical companies and repositions and promotes them to a determined niche marketplace.
 Recently, the company expanded its operations by hiring additional sales persons and headquarters staff.
 -0- 3/11/92 R
 /CONTACT: Richard Audet, chief financial officer of Bradley Pharmaceuticals, 201-882-1505/
 (BPRXA) CO: Bradley Pharmaceuticals, Inc. ST: New Jersey IN: MTC SU: ERN


KD-GK -- NY050 -- 7466 03/11/92 16:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1992
Words:224
Previous Article:RETIREES KEEP MEDICAL COVERAGE BUT PAY MORE FOR IT, WYATT REPORTS
Next Article:WANDA G. HENTON JOINS LAZARD FRERES
Topics:


Related Articles
BRADLEY PHARMACEUTICALS REPORTS RECORD QUARTERLY SALES AND SUCCESSFUL COMPLETION OF I.P.O. OVERALLOTMENT OFFERING
/C O R E C T I O N -- Bradley Pharmaceuticals Earnings
BRADLEY PHARMACEUTICALS REPORTS 131 PERCENT INCREASE IN FIRST QUARTER SALES
Bradley Pharmaceuticals Announces First Quarter 2000 Results.
Bradley Pharmaceuticals Increases Guidance Based on Positive First Quarter 2001 Sales and Earnings Results.
Bradley Pharmaceuticals Anticipated Third Quarter Sales and Earnings Growth Estimated to Exceed Guidance.
Bradley Pharmaceuticals Announces Developments Relating To Credit Facility and Convertible Notes.
Bradley Pharmaceuticals Announces Anticipated Timing of Financial Disclosures.
Bradley Pharmaceuticals to Present at the Bank of America 2007 Health Care Conference.
Bradley Pharmaceuticals to Report Second Quarter 2007 Financial Results and Schedules Conference Call.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters